Europe: Creating a digital hub for patients and caregivers

T2EVOLVE is a consortium working to accelerate the process of developing CAR T-cell therapy in the European Union (EU) to support patient access to this type of technology, while providing guidance on costs and implementation for EU healthcare systems.152
As part of their program, the consortium is developing a central digital hub for patients and caregivers, co-created with leading European patient advocacy groups and clinicians involved in CAR T-cell therapy. This will build on their existing patient hub, containing patient information resources co-created with Working Group of Patients and Caregivers (WGPC), EuroGCT, Acute Leukemia Advocate Network (ALAN), Myeloma Patients Europe (MPE) and Lymphoma Coalition.159 This additional platform aims to provide accessible, multilingual educational resources, practical guidance and support tools to empower patients and caregivers, thus enhancing patient’s understanding of their CAR T-cell therapy journey.158
References
152 Mikhael J, Fowler J, Shah N. Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access. JCO Oncol Pract. 2022;18(12):800-807. doi:10.1200/OP.22.00315
158 CMS. Fiscal Year (FY) 2021. Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Acute Care Hospital (LTCH) Final Rule (CMS-1735-F). Available online: https://www.cms.gov/newsroom/fact-sheets/fiscal-year-fy-2021-medicare-hospital-inpatient-prospective-payment-system-ipps-and-long-term-acute-0
159 T2EVOLVE. Patient Hub: What is CAR T-cell treatment? Available online: https://t2evolve.com/information-for-patients/what-is-car-t-cell-treatment/